New Data Highlights Superior Efficacy and Tolerability of Avextra 10/10 in Treating Chemotherapy-Induced Neuropathic Pain

News Release

Bensheim, Germany – 13 March 2025 – At the German Pain Association’s annual congress in Frankfurt, Germany, this week, researchers will present results from the OCEAN-R retrospective registry study. This study, supported by Avextra Pharma, a German biotech company focused on researching and developing cannabis-based medicines (CBMs), was presented at the annual congress in Frankfurt, Germany.

The OCEAN-R study demonstrates the effectiveness and safety of Avextra 10/10, a 1:1 balanced ratio THC/CBD extract, for treating Chemotherapy-Induced Neuropathic Pain (CINP).

OCEAN- R (CannabinOid extract for ChEmotherApie-induced neuropathic paiN)

A significant portion of cancer patients suffer from CINP, which often manifests as numbness in the extremities during treatment and can worsen into debilitating pain. CINP is a challenging side effect of chemotherapy, and conventional treatments provide little to no relief for up to 70% of patients.

The OCEAN-R study results indicate that Avextra’s extract offers a notably improved therapeutic outcome compared to standard guideline treatments for CINP.

Study Overview

The OCEAN-R study used a retrospective propensity score-matched analysis of 12-week routine data from the Database PraxisRegister Schmerz, comparing 442 patients treated with Avextra 10/10 to those receiving non-cannabis-based analgesics, including low and high potency opioids, antidepressants, and antiepileptics.

The study’s primary goal was to evaluate clinically significant improvements in pain intensity, quality-of-life measurements, and treatment tolerability. Key findings include:

  • Significant Pain Reduction: Patients treated with Avextra’s balanced THC/CBD extract had a greater decrease in pain intensity compared to those on non-cannabis-based medications.
  • Improved Quality of Life: The treatment group showed significant improvements in pain-related impairments and sleep quality.
  • Enhanced Tolerability: Treatment discontinuation due to adverse events was significantly lower in the Avextra 10/10 group (9.5%) compared to the group that did not receive cannabis treatment.

Dr. Michael A. Überall, the study’s lead researcher, stated, “The OCEAN-R study offers compelling evidence for patients with chemotherapy-induced neuropathic pain, demonstrating that the Avextra product is a valuable addition to the treatment options for this challenging condition.” Dr. Überall, Vice President of the German Pain Association, is a leading expert in pain management using cannabis-based medicines, with extensive published research in the area.

“This work demonstrates the German Pain Association’s (DGS) dedication to promoting strong clinical evidence that supports cannabis-based medicines as a viable option for treating pain and addressing unmet patient needs in this underserved population. We anticipate continuing our collaboration with Avextra and other partners to further investigate and validate these crucial treatment options,” stated Dr. Richard Ibrahim, President of the Association.

In addition to the OCEAN-R study, Dr. Ibrahim, the principal investigator of the IMPACT study, will present the IMPACT findings at the German Pain and Palliative Care Days. Additional information regarding IMPACT will be released separately.

“The OCEAN-R study marks a turning point in pain management. Avextra 10/10 not only surpasses traditional therapies in effectiveness and tolerability but also improves patients’ quality of life while significantly decreasing the need for opioids. This represents a breakthrough for patients who deserve better options,” said Bernhard Babel, CEO of Avextra.

About Avextra AG 

Avextra is a leading vertically integrated medical cannabis operator in Europe focused on creating and producing medicines approved by regulators. The company, founded in 2019 and located in Germany, collaborates closely with doctors, pharmacists, and researchers to develop and produce cutting-edge cannabis-based medicines. Avextra manages the entire value chain, from cultivation in Portugal to EU-GMP certified extraction and manufacturing in Germany. Avextra operates throughout continental Europe using a broad distribution network of multiple channels and strategically developed assets for these key markets. 

Find out more at avextra.com and stay informed at LinkedIn: LinkedIn.com/company/avextra-ag/ 

Avextra Media Enquiries:  

For media inquiries or to arrange an interview, please contact: 

Email: press@avextra.com 

Phone: +49 30 408174037 

“`